Literature DB >> 20673814

Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders.

Björn C Knollmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20673814      PMCID： PMC2970718          DOI： 10.1016/j.hrthm.2010.07.028

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN： 1547-5271            Impact factor:   6.343


× No keyword cloud information.
  13 in total

1.  Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.

Authors:  Guy Katz; Assad Khoury; Efrat Kurtzwald; Edith Hochhauser; Eyal Porat; Asher Shainberg; Jonathan G Seidman; Christine E Seidman; Abraham Lorber; Michael Eldar; Michael Arad
Journal:  Heart Rhythm       Date:  2010-07-08       Impact factor: 6.343

2.  Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Björn C Knollmann; Nagesh Chopra; Thinn Hlaing; Brandy Akin; Tao Yang; Kristen Ettensohn; Barbara E C Knollmann; Kenneth D Horton; Neil J Weissman; Izabela Holinstat; Wei Zhang; Dan M Roden; Larry R Jones; Clara Franzini-Armstrong; Karl Pfeifer
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

3.  Effects of changes in left ventricular contractility on indexes of contractility in mice.

Authors:  Shintaro Nemoto; Gilberto DeFreitas; Douglas L Mann; Blase A Carabello
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-12       Impact factor: 4.733

4.  Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death.

Authors:  Dawei Jiang; Ruiwu Wang; Bailong Xiao; Huihui Kong; Donald J Hunt; Philip Choi; Lin Zhang; S R Wayne Chen
Journal:  Circ Res       Date:  2005-10-20       Impact factor: 17.367

5.  Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Rafael Rosso; Jonathan M Kalman; Ori Rogowski; Shmuel Diamant; Amir Birger; Simon Biner; Bernard Belhassen; Sami Viskin
Journal:  Heart Rhythm       Date:  2007-05-24       Impact factor: 6.343

6.  Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.

Authors:  Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

Review 7.  A genetic framework for improving arrhythmia therapy.

Authors:  Björn C Knollmann; Dan M Roden
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

8.  Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.

Authors:  Lei Song; Ronny Alcalai; Michael Arad; Cordula M Wolf; Okan Toka; David A Conner; Charles I Berul; Michael Eldar; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 9.  Catecholaminergic polymorphic ventricular tachycardia.

Authors:  Johnson Francis; Vikram Sankar; Venugopal Krishnan Nair; Silvia G Priori
Journal:  Heart Rhythm       Date:  2005-05       Impact factor: 6.343

10.  Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.

Authors:  Nian Liu; Barbara Colombi; Mirella Memmi; Spyros Zissimopoulos; Nicoletta Rizzi; Sara Negri; Marcello Imbriani; Carlo Napolitano; F Anthony Lai; Silvia G Priori
Journal:  Circ Res       Date:  2006-07-06       Impact factor: 17.367
View more
  6 in total

1.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

Review 2.  Calsequestrin 2 and arrhythmias.

Authors:  Michela Faggioni; Björn C Knollmann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-23       Impact factor: 4.733

3.  Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.

Authors:  Przemysław B Radwański; Lucia Brunello; Rengasayee Veeraraghavan; Hsiang-Ting Ho; Qing Lou; Michael A Makara; Andriy E Belevych; Mircea Anghelescu; Silvia G Priori; Pompeo Volpe; Thomas J Hund; Paul M L Janssen; Peter J Mohler; John H B Bridge; Steven Poelzing; Sándor Györke
Journal:  Cardiovasc Res       Date:  2014-12-23       Impact factor: 10.787

Review 4.  Genetics of sudden cardiac death syndromes.

Authors:  Nagesh Chopra; Björn C Knollmann
Journal:  Curr Opin Cardiol       Date:  2011-05       Impact factor: 2.161

5.  Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hiroshi Watanabe; Christian van der Werf; Ferran Roses-Noguer; Arnon Adler; Naokata Sumitomo; Christian Veltmann; Raphael Rosso; Zahurul A Bhuiyan; Hennie Bikker; Prince J Kannankeril; Minoru Horie; Tohru Minamino; Sami Viskin; Björn C Knollmann; Jan Till; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2012-12-31       Impact factor: 6.343

6.  Neuronal Na+ Channels Are Integral Components of Pro-arrhythmic Na+/Ca2+ Signaling Nanodomain That Promotes Cardiac Arrhythmias During β-adrenergic Stimulation.

Authors:  Przemysław B Radwański; Hsiang-Ting Ho; Rengasayee Veeraraghavan; Lucia Brunello; Bin Liu; Andriy E Belevych; Sathya D Unudurthi; Michael A Makara; Silvia G Priori; Pompeo Volpe; Antonis A Armoundas; Wolfgang H Dillmann; Bjorn C Knollmann; Peter J Mohler; Thomas J Hund; Sándor Györke
Journal:  JACC Basic Transl Sci       Date:  2016-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.